We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8). The PROTAC induced degradation of HDAC8 without affecting the levels of other HDACs in cellular assays, and inhibited the growth of T-cell leukemia Jurkat cells more potently than a conventional HDAC8 inhibitor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d2cc00272h | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!